Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 4—April 2022
Research

SARS-CoV-2 IgG Seroprevalence among Blood Donors as a Monitor of the COVID-19 Epidemic, Brazil

Daniel Gonçalves Chaves1Comments to Author , Ricardo Hiroshi Caldeira Takahashi1, Felipe Campelo, Maria Clara Fernandes da Silva Malta, Isabelle Rocha de Oliveira, Edel Figueiredo Barbosa-Stancioli, Maísa Aparecida Ribeiro, and Marina Lobato Martins
Author affiliations: Fundação Hemominas, Belo Horizonte, Brazil (D.G. Chaves, M.C.F. da Silva Malta, M.A. Ribeiro, M.L. Martins); Universidade Federal de Minas Gerais, Belo Horizonte (R.H.C. Takahashi, F. Campelo, I.R. de Oliveira, E.F. Barbosa-Stancioli); Aston University, Birmingham, UK (F. Campelo)

Main Article

Table

Characteristics and severe acute respiratory syndrome coronavirus 2 IgG seroprevalence among blood donors, Brazil, March–December 2020

Characteristics Total samples Positive samples Unadjusted seroprevalence, % (95% CI) Test-adjusted seroprevalence, % (95% CI)* Odds ratio (95% CI)
Total
 7,837
 441
 5.6 (5.1–6.2)
 5.2 (4.7–5.8)
Sex
M 4,284 273 6.4 (5.7–7.1) 6.0 (5.3–6.9) 1.4 (1.1–1.6)
F
 3,553
 168
 4.7 (4.1–5.5)
 4.2 (3.5–5.0)
Age range, y
16–30 2,895 153 5.3 (4.5–6.2) 4.8 (4.0–5.8)
31–40 2,330 135 5.8 (4.9–6.8) 5.4 (4.4–6.5)
41–50 1,701 115 6.8 (5.7–8.1) 6.5 (5.3–7.9)
51–60 829 32 3.9 (2.8–5.4) 3.2 (2.0–4.9)
61–70
 82
 6
 7.3 (3.4–15.1)
 7.1 (2.7–15.8)
Donor type
First-time donor 1,483 72 4.9 (3.9–6.1) 4.3 (3.2–5.7) 0.8 (0.7–1.1)
Repeat donor 6,353 369 5.8 (5.3–6.4) 5.4 (4.8–6.1)

*Considering sensitivity of 90% and specificity of 99%. Analysis performed by Epitool by using Wilson’s confidence interval for apparent rate of positivity and Blaker’s CI for true rate of positivity.

Main Article

1These authors contributed equally to this article.

Page created: February 09, 2022
Page updated: March 19, 2022
Page reviewed: March 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external